

CORPORATE PROFILE

Precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care.

4 Science Park New Haven, CT 06511 Phone: 1.203.787.7888 Fax: 1.203.901.1289


http://www.precipiodx.com/index.html

info@precipiodx.com

CORE IR Scott Gordon President 377 Oak Street Garden City, NY 11530 516.222.2560 www.coreir.com scottg@coreir.com

STOCK PERFORMANCE

Symbol	prpo
Exchange	NSC
Market Cap.	7.58m
52 Week Range	0.4601 - 28.16
Close	0.9001
Volume	7
Shares Outstanding	12,732,527
As of Mar 21, 2018 2:39 pm	



MANAGEMENT TEAM

Ilan Danieli - Founder & CEO

Carl Iberger - CFO

Stephen Miller - Chief Commercial Officer

Zaki Sabet - Chief Operating Officer

Ayman Mohamed - VP R&D

BOARD OF DIRECTORS

Samuel D. Riccitelli - Chairman of the Board of Directors

Jeffrey Cossman, MD - Director

Doug Fisher, MD - Director

Ilan Danieli - CEO & Director

Mark Rimer - Director

David Cohen - Director

Michael A. Luther, Ph.D. - Director

RECENT HEADLINES

Mar 20, 2018 - Precipio Integrates Cost Reducing and Fast Turnaround "High Resolution Melt" into Liquid Biopsy Platform

Mar 13, 2018 - Precipio Settles Lawsuit with Crede Capital

Feb 22, 2018 - Key Measure of Precipio's Pathology Sales Growth 4X Prior Quarter

Feb 15, 2018 - Precipio Launches Unique Lung Cancer Monitoring Test for Therapy Resistance

Feb 9, 2018 - Precipio Announces Q4 2017 Revenue at 350% of Previous Quarter

PAST EVENTS

Nov 21, 2017 - Q3 2017 Earnings Results and Business Update Conference Call Sep 12, 2017 - 4:30pm Business Update Conference Call